Duke Human Vaccine Institute

• 

  People

  • Primary Appointments

    • Prasad, Avvari V. Krishna, Adjunct Assistant Professor in the Department of Medicine

  • Secondary Appointments

    • Staats, Herman Ford, Associate Professor of Medicine

  • Memberships

    • Acharya, Priyamvada, Member of the Duke Human Vaccine Institute
    • Alam, S. Munir, Member of the Duke Human Vaccine Institute
    • Azoitei, Mihai Luchian, Member of the Duke Human Vaccine Institute
    • Blasi, Maria, Member of the Duke Human Vaccine Institute
    • Cain, Derek Wilson, Member of the Duke Human Vaccine Institute
    • Denny, Thomas Norton, Member of the Duke Human Vaccine Institute
    • Edwards, Robert J, Member of the Duke Human Vaccine Institute
    • Ferrari, Guido, Member of the Duke Human Vaccine Institute
    • Fouda, Genevieve Giny, Member of the Duke Human Vaccine Institute
    • Frothingham, Richard, Member of the Duke Human Vaccine Institute
    • Gao, Feng, Member of the Duke Human Vaccine Institute
    • Hale, Laura Pope, Member of the Duke Human Vaccine Institute
    • Haynes, Barton Ford, Member of the Duke Human Vaccine Institute
    • Heaton, Nicholas Scott, Member of the Duke Human Vaccine Institute
    • Katz, Samuel L., Member of the Duke Human Vaccine Institute
    • Kelsoe, Garnett H., Member of the Duke Human Vaccine Institute
    • Klotman, Mary E, Member of the Duke Human Vaccine Institute
    • Lee, Sunhee, Member of the Duke Human Vaccine Institute
    • Liao, Hua-Xin, Member of the Duke Human Vaccine Institute
    • Montefiori, David Charles, Member of the Duke Human Vaccine Institute
    • Moody, Michael Anthony, Member of the Duke Human Vaccine Institute
    • Permar, Sallie Robey, Member of the Duke Human Vaccine Institute
    • Pickup, David James, Member of the Duke Human Vaccine Institute
    • Pisetsky, David Stephen, Member of the Duke Human Vaccine Institute
    • Pollara, Justin Joseph, Member of Duke Human Vaccine Institute
    • Sarzotti-Kelsoe, Marcella, Member of the Duke Human Vaccine Institute
    • Saunders, Kevin O'Neil, Member of the Duke Human Vaccine Institute
    • Sempowski, Gregory David, Member of the Duke Human Vaccine Institute
    • Shen, Xiaoying, Member of the Duke Human Vaccine Institute
    • Sleasman, John William, Member of the Duke Human Vaccine Institute
    • Smith, Clare, Member of the Duke Human Vaccine Institute
    • Spicer, Leonard D., Member of the Duke Human Vaccine Institute
    • Staats, Herman Ford, Member of the Duke Human Vaccine Institute
    • Steinbach, William J., Member of the Duke Human Vaccine Institute
    • Swamy, Geeta Krishna, Member of the Duke Human Vaccine Institute
    • Tomaras, Georgia Doris, Member of the Duke Human Vaccine Institute
    • Walter Jr., Emmanuel Benjamin, Member of the Duke Human Vaccine Institute
    • Weinhold, Kent James, Member of the Duke Human Vaccine Institute
    • Wiehe, Kevin J, Member of the Duke Human Vaccine Institute
    • Williams, Wilton Bryan, Member of the Duke Human Vaccine Institute
    • Zhang, Zhao, Member of the Duke Human Vaccine Institute
• 

  Administers Grant

  • 2020 CISA 04-COVID Maternal Study
  • A Double-Blind, Randomized, Placebo-controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults
  • A Magnetic Microparticle Kit for Cell Removal from Blood
  • A PHASE 1, OPEN-LABEL DOSE-FINDING AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN 5 TO 12 YEARS OF AGE
  • A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINS
  • A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2
  • A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T
  • ABL UFO Project Task Order
  • ACTG EIA-Luminex Biomarker Supplement (Phase I)
  • Abbott CSA
  • Acceleration of antibody production to conduct passive immunity NHP studies
  • Adaptive COVID-19 Treatment Trial (ACTT)
  • Administrative Supplement to CHAVI for GWAS Meta-Analyses
  • Administrative Supplement to the CHAVI for ALVAC NHP Study
  • Administrative supplement to CHAVI-ID to study novel vaccines based on 5' leader HIV/SIV immunogens
  • An open-label, pilot study to compare the safety and immunogenicity of an alternate dosing schedule (2-5 weeks, 2, and 4 months) for pentavalent rotavirus vaccine (RotaTeq) to the standard recommended schedule (2, 4 and 6 months).
  • An orally bioavailable broad-spectrum Hsp90 inhibitor (Hsp90i) therapy to suppress emerging Coronavirus (CoV) infections
  • Analysis of Germinal Center Responses to HIV-1 Envelope
  • Animal Models of Infectious Diseases Part A
  • Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination
  • Antibody and viral determinants of protection against CMV infection in the gB/MF59 vaccination cohort
  • Antibody responses in pediatric cystic fibrosis cohort
  • Antigen recognition and activation of B-cell receptors of HIV-1 broadly neutralizing antibodies
  • Automated detection of protein crystals in high-throughput crystallography experiments
  • Avioq _VioOne HIV Profile Supplement Assay Project
  • B-cell repertoire analysis in influenza vaccination and infection
  • Biomarker analysis of vaginal lavage samples
  • Broad neutralizing antibodies against HIV-1 from RV217 participants
  • CARE Duke-UNC Latency Biomarker Supplement Year 2
  • CARE Focus 1: Latency Biomarker Project
  • CARE Focus 2: Clearance of HIV Antigen-Positive Cells
  • CECI Supplement
  • CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Base
  • CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 1
  • CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 2
  • CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 3
  • CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 4
  • CISA 07 Adult RCT COVID-19 Vaccination (Lead)
  • CISA 10-Pediatric COVID-19 Vaccination (Lead)
  • CISA 2017 06 - Clinical Consult - Base
  • CISA 2017 06 - Clinical Consult - Opt 1
  • CISA 2017 06 - Clinical Consult - Opt 2
  • CISA 2018-2019 - Clinical Consult - Opt 2
  • CISA 2018-2019 - Clinical Consult - Opt 2
  • CISA 2018-2019 - Clinical Consult - Base
  • CISA 2018-2019- Clinical Consult - Opt 1
  • CISA 2020-2021 - Clinical Consult - Opt 2
  • CISA 2020-2021 - Clinical Consult - Base
  • CISA 2020-2021- Clinical Consult - Opt 1
  • CISA Clinical Consult TO I - Option 4
  • CISA RFTP Syncope Prevention Study (Lead) 2020-2022
  • CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Base
  • CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 1
  • CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 2
  • CISA RTOP 2017-01 Apnea (Lead) - Base
  • CISA RTOP 2017-01 Apnea (Lead) - Option 1
  • CISA RTOP 2017-01 Apnea (Lead) - Option 2
  • CISA Shingrix 2020 Lead Site Task 2
  • CISA TO2 Prophylactic Antipyretics Revision 1-A
  • CISA TO2 Prophylactic Antipyretics Revision 3-A
  • CISA Task Order No. 3 Tdap Safety in Pregnant Women
  • CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 1-CLIN0002
  • CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 2-CLIN0003
  • CISA: 2015 CISA 02 - Contributing Site Base Task: Consultation for the LAIV and Asthma Study (Contributing)
  • CISA: 2015 CISA 02 - Contributing Site Optional Task 1: Enrollment and Data Collection for the LAIV and Asthma Study (Contributing)
  • CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
  • CISA: 2015 CISA 03 - Lead Site Optional Task 1 (Combined Options 1-11): Additional Subjects for Maternal Tdap and IIV Study (Lead)
  • CISA: 2015 CISA 03 - Lead Site Optional Task 1: Additional Subjects for Maternal Tdap and IIV Study (Lead)
  • CIVICS A - Option 23B
  • CIVICS Component A - Option 1
  • CIVICS Component C - Option 1
  • CIVICS Component C - Option 13A
  • CIVICS Component C - Option 16
  • CIVICS Component C - Option 8
  • CIVICS Component C - Option 8 B.1
  • CIVICS Component C - Option 9
  • CIVICs A - Option 18A SAVE Aims 1, 2
  • CIVICs A - Option 18B SAVE Aim 3
  • CIVICs A - Option 23A
  • CIVICs Component B: Base - Option 1
  • CIVICs Component B: Option 7
  • CIVICs Component B: Option 8
  • CIVICs Component B: Option 9
  • CIVICs Component C - Option 13A.1 Equitable Adjustment
  • Center for HIV/AIDS Vaccine Immunology (CHAVI)
  • Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
  • Centralized HIV-1 Genes as Vaccines
  • Characterization BCG-Gag immunized macaques
  • Characterization of antibody subclasses and ADCC activity in RV305 extended, RV306, and RV328 clinical trial subjects
  • Chronic Fatigue Initiative Bio-Bank
  • Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3
  • Comprehensive T cell Vaccine Immune Monitoring Consortium (CTVIMC)
  • Core C: Immunology
  • Core C: Monitoring Host Response
  • Core D: Human Translation and Verification
  • Coronavirus Vaccine Design
  • Creation of a bnAbnectin
  • Critical domains for HIV-1 entry through atypical coreceptor usage
  • Cytometry Analysis of Adamas Diamond Particles
  • Defining and Redirecting Influenza Immunity After Imprinting
  • Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
  • Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
  • Development of a nonhuman primate model of fetal Zika virus infection and disease
  • Development of broadly neutralizing antibody responses in HIV-infected children
  • Duke Clinical Good Manufacturing Practices Facility for HIV/AIDS Vaccine Production
  • Duke DARPA Pandemic Prevention Platform (P3)
  • Duke Infectious Disease Response Training Consortium (DIDRT)
  • Duke Subaward to Ology Bio Project Galaxy
  • EQAPOL - 2016 to 2017 - Option 6 - BASE
  • EQAPOL - 2016 to 2017 - Option 6 - FLOW
  • EQAPOL - 2016 to 2017 - Option 6 - VIRUS
  • EQAPOL - Option 48 - 2016 to 2017 - A3R5
  • EQAPOL - Option 48 - 2016 to 2017 - LUMINEX
  • EQAPOL - Option 6 - 2016 to 2017 - ELISPOT
  • EQAPOL - Years 2017 to 2024 - BASE
  • EQAPOL ELISpot Proficiency Testing Program
  • EQAPOL Option 47
  • EQAPOL Option 5
  • EQAPOL SARS CoV-2 EQA Option 42
  • Early Infection Response
  • Early Life Vaccination to Prevent HIV acquisition during Adolescence
  • Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens
  • Emerging Infectious Diseases - Coordination Center
  • Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
  • Epigenetic Control of the CD8+ T-cell Response to HIV
  • Eqapol Opt 3 -2020-2021
  • Experimental Human Infection with Isogenic Mutants of Neisseria gonorrhoeae
  • External Quality Assurance Program Oversight Laboratory
  • Focus 1: Detection of HIV Antigen-Positive Cells
  • Functional profile to HIV vaccine elicited antibodies in infants
  • Gonorrhea Vaccine Cooperative Research Center (GV-CRC); Core C: Host Response Monitoring
  • HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants
  • HIV Research for Prevention 2018: Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P)
  • HIV-1 vaccine-elicited antibodies target envelope glycans
  • HVTN 3002 Protocol Funding (PF) - Durham Protocol-Specific Site
  • HVTN Phase 1 Protocol Funding
  • Harnessing Antibody-Mucus Interaction to Prevent HIV Transmission
  • Harriet Robinson GeoVax B63521 PPF
  • Humoral and cellular immunity during acute HIV-1
  • Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women
  • Hyperimmune globulin treatment of Zika virus during pregnancy to reduce Congenital Zika Syndrome
  • IMPAACT 2021 Core funding PTCL 11
  • IMPAACT PTCL 10 MOD 03 PF Y14
  • IMPAACT Trial--13 CF
  • IMPAACT trial
  • IQA Option 18 - UK NEQAS Proficiency Testing Cryo
  • IQA Option 25 -PBMC Cryopreservation Proficiency Testing
  • IQA Option 4
  • Identifying key determinants of IgG transplacental transfer from HIV-infected mothers to their fetus
  • Identifying key determinants that modulate maternal IgG transplacental transfer to the fetus
  • Identifying maternal immune correlates of protection against perinatal mother-to-child transmission (MTCT) in a large cohort of clade C HIV infected women
  • Immune Correlates of Protection Against Congenital Cytomegalovirus Transmission in an HIV-Infected Mother-Infant Cohort
  • Immunogen Design Strategies To Direct Hiv-1 Broadly Neutralizing Antibody Maturation By Probability-Based Targeting Of Critical Mutations
  • Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
  • Immunogen Design of HIV Sequential Envelopes Derived from SHIV-infected Macaques
  • Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques-Supplement
  • Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
  • Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys-Admin Core
  • Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys-Diversity suppl
  • Immunological Correlates of Syphilis Protection
  • Immunology Quality Assesment Program 2021-2028
  • Immunology Quality Assesment Program Option 2
  • Immunology Quality Assesment Program Options 1-6
  • Immunology Quality Assessment Program - Option 41
  • Immunology Quality Assessment Program Option 3
  • Immunology Quality Assessment Program Year 5
  • Immunology Quality Assessment Program Year 7
  • Indexus Contract
  • Induction of protective antibodies for HIV vaccine development
  • Infant immune correlates of perinatal mother to child transmission of HIV
  • Innate antiviral factors in breast milk and the oral HIV-1 reservoir
  • International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Group
  • Isolation of protective ZIKV-neutralizing maternal monoclonal antibodies for safe prophylactic use in the preconception period
  • LOC-IMPAACT Leadership Group
  • Langorin-eOD project
  • Lead Site Task 1: Simultaneous RZV and all V4 Vaccination (Lead)
  • Letvin Gates Mycobacteria Grant
  • METHODS TO TEST LIFESTYLE, VAGINAL MICROENVIRONMENT, AND GENITOURINARY SYMPTOMS ACROSS MENOPAUSE TRANSITION
  • Macrogenics Cytokine Profiling Subcontract
  • Maternal immune protection against congenital CMV infection
  • McElrath Objective 3-Evaluate potential mucosal quality indicators
  • McElrath Objective 3-Evaluate potential mucosal quality indicators
  • Mechanisms controlling induction of HIV V1V2 glycan broadly neutralizing antibodies
  • Mechanisms of Age Induced Thymic Atrophy
  • Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
  • Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
  • Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
  • Molecular signatures of broad neutralization in HIV infected children
  • Mucosal antibody protection against postnatal SIV transmission in natural hosts of SIV
  • Mycobacterial Genes Responsible for Regulating Autophagy
  • NIAID Virology Quality Assurance - Options 27 Only
  • NIAID Virology Quality Assurance - Year 3 Option 2
  • NIAID Virology Quality Assurance - Year 3 Option 28
  • NSF Grad Res Fellowship Prog Perley
  • Natural killer cell regulation of the germinal center HIV neutralizing antibody response
  • Natural killer cell regulation of the germinal center HIV neutralizing antibody response
  • Neonatal Immunity to novel TF SHIVs
  • Neutralizing and non-neutralizing antibody effector functions in HIV infected children
  • Non-human Primate Binding Antibody Evaluation
  • Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Base
  • Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Base Year 4 - Option 3
  • Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 10 Year 4
  • Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 15
  • Novel nanoparticle platform for antiviral vaccine and therapeutics
  • Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies
  • OPP 1114721 - Supplement to RV144
  • Option Three (3) of Contract No. 200-2012-53663, Task Order 0001
  • P186 Research Analysis
  • Permar IMPAACT 2004 stability study QAU
  • Personality and Health in Later Life: Psychosocial and Biological Mechanisms
  • Pilot studies to translate human diagnostics in NHP models
  • Pre-infection B cell repertoire primed by the gut commensal bacteria enhances post-infection SIV envelope gp120-specific antibody response in African green monkey
  • Production of HIV-1 Envs #2
  • Production of cGMP 16055 NFL Trimer
  • Project 1: Immune correlates of cCMV
  • Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responses
  • Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responses
  • Project 2: The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
  • Protein Production Facility
  • QBI - reagent support quote
  • RERF year 7 funding
  • RFTP 2016 CISA 01 - Base - FLUAD vs. Fluzone® High-Dose Study (Lead)
  • RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
  • RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
  • RFTP 2018 CISA 05 FLUAD Logical Follow On Task 1
  • RTOP 2018 CISA 01 Flublok Lead Base
  • RTOP 2018 CISA 01 Flublok Lead Task 1
  • RTOP 2018 CISA 01 Flublok Lead Task 2
  • RTOP 2018 CISA 01 Flublok Lead Task 3
  • RTOP 2018 CISA 01 Flublok Lead Task 4
  • Radiation Survival Cohort - Immune Monitoring Core
  • Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections
  • Rapid, Near Patient Nucleic Acid Testing for Infant Cytomegalovirus (CMV) Infection
  • Recombinant vectored delivery of maternal antibody for transfer into breast milk and across the placenta
  • Reducing disparities in adolescent HPV vaccination coverage in the Carolinas
  • Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT
  • SIV-specific immunity in breast milk during infection and after vaccination
  • SRA - EQAPOL Luminex Program - CSL Limited
  • SRA - EQAPOL Luminex Program - Peter MacCallum Cancer Centre
  • Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants
  • Seraworx - EQAPOL ELISPOT SRA
  • Simple interventions to Improve Rotavirus Vaccine Effectiveness (SIRVE)
  • Statistical methods for HIV-1 immune correlates studies
  • Strategies to Target CMV Glycoprotein B Antigenic Domain-2 by B Cell Lineage Maps
  • Structure, dynamics and evolution of the HIV-1 Phe-43 cavity
  • Structure-function Analysis of Infection and Vaccine Induced B-Cell Reoertiures-Supplement
  • Structures of initial CD4 engagement with pre-fusion, closed HIV-1 Envelope trimer and early CD4-induced conformational changes required for infection
  • Studying the effect on HIV-1 Env structure and immune response to HIV-1 infection in mucosal fluids using Negative Stain Electron Microscopy
  • Subcontract from Pax Vax for production of 4 505 gp140 proteins
  • Subcontract from UAB for Tetramer Production
  • Supramolecular pediatric HIV vaccine design
  • Synthesis of V3 scaffolds
  • T Cell and Monocyte Telomere Length Dynamics in Patients with COVID-19
  • Targeting natural killer cells to enhance HIV vaccine responses
  • Task Area B-D Task Order 16-0058.B1C1D1.0076
  • Testing of Adrenas Therapeutics AAV vectors in mice
  • Testing of Aspa Therapeutics AAV vectors in mice
  • Testing the ability of antibody-mucin interactions to provide vaccine function
  • The B cell repertoire and antibody maturation elicited by adjuvanted HIV envelope vaccines in infants
  • The duality of vaccine elicited HIV specific-IgA antibodies: Providing protection or diminishing protection
  • The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
  • The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
  • The relationship between maternal ZIKV-specific and ADE antibodies and fetal outcome
  • Transmission-blocking potential of novel HIV Env-specific mucosal antibodies
  • Universal Ebola Vaccine Antigen Design and Testing in a Mouse Model
  • VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D PHASE 1 PK TRIAL TO EVALUATE FOSFOMYCIN TASK ORDER 16-0058.B1C1D1.0076
  • VTEU 12-0016: Task Area C: Protocol implementation
  • VTEU 12-0021 - Task C Option 1
  • VTEU 12-0021 Task C - Base
  • VTEU 13-0053 FY 2020 Option 1-Protocol Implementation
  • VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
  • VTEU 14-0053 Task Area A Project Logistics and Site Activation
  • VTEU 14-0053 Task C Option 2 Protocol Implementation
  • VTEU 14-0053 Task C Option 3 Protocol Implementation
  • VTEU 14-0053 Task C Option 4 Protocol Implementation
  • VTEU 18-0010.B1C1.0120_Task B Base
  • VTEU 18-0010.B1C1.0120_Task C Option 1
  • VTEU FY.2018.A1B1C1D1.0077 - Task A - Option 1
  • VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base
  • VTEU Protocol Implementation Option 1
  • VTEU RTOP 16-0027.C1D1.0079 - Task Area C Base
  • VTEU RTOP 16-0027.C1D1.0079 - Task Area D-Option 3
  • VTEU RTOP FY.2017.B8C12.0080 - Task B
  • VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 1
  • VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 3
  • VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 8
  • VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
  • VTEU Sample Task Orders
  • VTEU Task A Base - FY.2017.A1B1C1D1.0048
  • VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048
  • VTEU Task A Protocol FY.2015.A4D14.0033
  • VTEU Task Area A - FY.2015.A1.0016 Base
  • VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
  • VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base-A
  • VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
  • VTEU Task Area A, Base Protocol FY.2016.A1.0026
  • VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
  • VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
  • VTEU Task Area B Protocol 15-0020.B1C1.0040
  • VTEU Task Area C Option 1 Protocol 15-0020.B1C1.0040
  • VTEU Task Area C Option 2-1 Protocol 15-0020.B1C1.0040
  • VTEU Task Area C Option 2-2 Protocol 15-0020.B1C1.0040
  • VTEU Task Area C Option 2-3 Protocol 15-0020.B1C1.0040
  • VTEU Task Area C Option 3 Protocol FY.2016.C1.0026
  • VTEU Task Area C Option 3B Protocol FY.2016.C1.0026
  • VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
  • VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
  • VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
  • VTEU Task B - FY.2017.B2C2D2.0053
  • VTEU Task B Base Protocol 14-0079.B1C1.0028
  • VTEU Task B Base Protocol 15-0066.B1C1D1.0041
  • VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048
  • VTEU Task C Base Protocol 14-0024.C1D1.0037
  • VTEU Task C Option 1 - FY.2017.B2C2D2.0053
  • VTEU Task C Option 1 Protocol 14-0024.C1D1.0037
  • VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
  • VTEU Task C Option 1 Protocol 15-0066.B1C1D1.0041
  • VTEU Task C Option 2 - FY.2017.B2C2D2.0053
  • VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
  • VTEU Task C Option 3 - FY.2017.B2C2D2.0053
  • VTEU Task C Option 4 - FY.2017.B2C2D2.0053
  • VTEU Task D Option 1 Protocol FY.2015.A4D14.0033
  • VTEU Task D Option 2 Protocol 14-0024.C1D1.0037
  • VTEU Task D Option 2 Protocol FY.2015.A4D14.0033
  • VTEU Task D Option 3 Protocol 14-0024.C1D1.0037
  • VTEU Task D Option 3 Protocol FY.2015.A4D14.0033
  • VTEU Task D Option 4 Protocol 14-0024.C1D1.0037
  • VTEU Task D Option 4 Protocol FY.2015.A4D14.0033
  • VTEU Task D Option 5 - FY.2017.B2C2D2.0053
  • VTEU Task D Option 5 Protocol 14-0024.C1D1.0037
  • VTEU Task D Option 6 - FY.2017.B2C2D2.0053
  • VTEU Task D Protocol FY.2015.D1B1C1.0032
  • VTEU Task Order 13-0045.C1D1.0062 - Task C Option 1
  • VTEU Task Order 13-0045.C1D1.0062 - Task D
  • VTEU Task Order 16-0047 -Task C Option 1
  • VTEU Task Order 16-0047.C1.0090
  • VTEU Task Order 16-0058.B1C1D1.0076 - Task D
  • VTEU Task Order 18-0011.B1.C1.0116-Task B Base
  • VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053
  • VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053
  • VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053
  • VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
  • Vaccine and Treatment Evaluation Units (VTEU)
  • Validation of the ADAMANT Platform
  • Virology Core
  • Virology Core: The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
  • Whole genome sequencing of 100 high risk, uninfected individuals
  • Whole genome sequencing of rhesus macaques
  • Zika virus pathophysiology during pregnancy
  • cGMP Manufacturing of an HIV-1 Env Nanoparticle

Add data to my Website